Citigroup Inc Uni Qure N.V. Call Options Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 12, 2024	BUY	$4.39 - $5.43 $195,794 - $242,178	44,600 New	44,600 $199,000
Q2 2023 Aug 10, 2023	SELL	$11.12 - $22.2 $302,464 - $603,840	-27,200 Reduced 47.72%	29,800 $341,000
Q1 2023 May 11, 2023	SELL	$18.7 - $23.07 $93,500 - $115,350	-5,000 Reduced 8.06%	57,000 $1.15 Million
Q4 2022 Feb 09, 2023	SELL	$18.12 - $27.32 $115,968 - $174,848	-6,400 Reduced 9.36%	62,000 $1.41 Million
Q3 2022 Nov 10, 2022	BUY	$16.98 - $25.54 $331,110 - $498,030	19,500 Added 39.88%	68,400 $1.28 Million
Q2 2022 Aug 10, 2022	BUY	$13.15 - $20.45 $643,035 - $1 Million	48,900 New	48,900 $911,000

154

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $793M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.